Gavestinel Sodium | CAS#153436-38-5 | CAS#153436-22-7 | glycine-site antagonist

MedKoo Cat#: 529421 | Name: Gavestinel Sodium

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Gavestinel Sodium is an NMDA glycine-site antagonist potentially for the treatment of stroke.

Chemical Structure

Gavestinel Sodium

CAS#153436-38-5 (sodium)

Theoretical Analysis

MedKoo Cat#: 529421

Name: Gavestinel Sodium

CAS#: 153436-38-5 (sodium)

Chemical Formula: C18H11Cl2N2NaO3

Exact Mass:

Molecular Weight: 397.18

Elemental Analysis: C, 54.43; H, 2.79; Cl, 17.85; N, 7.05; Na, 5.79; O, 12.08

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

153436-22-7 (free base) 153436-38-5 (sodium)

Synonym

GV-150526A; GV150526A; GV 150526A

IUPAC/Chemical Name

sodium (E)-4,6-dichloro-3-(3-oxo-3-(phenylamino)prop-1-en-1-yl)-1H-indole-2-carboxylate

InChi Key

GRSDSTMFQHAESM-UHDJGPCESA-M

InChi Code

InChI=1S/C18H12Cl2N2O3.Na/c19-10-8-13(20)16-12(17(18(24)25)22-14(16)9-10)6-7-15(23)21-11-4-2-1-3-5-11;/h1-9,22H,(H,21,23)(H,24,25);/q;+1/p-1/b7-6+;

SMILES Code

O=C(C(N1)=C(/C=C/C(NC2=CC=CC=C2)=O)C3=C1C=C(Cl)C=C3Cl)[O-].[Na+]

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 397.18 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Martin-Flores M, Cheetham J, Campoy L, Sakai DM, Heerdt PM, Gleed RD. Effect of gantacurium on evoked laryngospasm and duration of apnea in anesthetized healthy cats. Am J Vet Res. 2015 Mar;76(3):216-23. doi: 10.2460/ajvr.76.3.216. PubMed PMID: 25710757. 2: Sunaga H, Zhang Y, Savarese JJ, Emala CW. Gantacurium and CW002 do not potentiate muscarinic receptor-mediated airway smooth muscle constriction in guinea pigs. Anesthesiology. 2010 Apr;112(4):892-9. doi: 10.1097/ALN.0b013e3181d32016. PubMed PMID: 20216393; PubMed Central PMCID: PMC2854830. 3: Savarese JJ, McGilvra JD, Sunaga H, Belmont MR, Van Ornum SG, Savard PM, Heerdt PM. Rapid chemical antagonism of neuromuscular blockade by L-cysteine adduction to and inactivation of the olefinic (double-bonded) isoquinolinium diester compounds gantacurium (AV430A), CW 002, and CW 011. Anesthesiology. 2010 Jul;113(1):58-73. doi: 10.1097/ALN.0b013e3181dc1b5b. PubMed PMID: 20526187. 4: Naguib M, Brull SJ. Update on neuromuscular pharmacology. Curr Opin Anaesthesiol. 2009 Aug;22(4):483-90. doi: 10.1097/ACO.0b013e32832b8cff. Review. PubMed PMID: 19384229. 5: Heerdt PM, Sunaga H, Savarese JJ. Novel neuromuscular blocking drugs and antagonists. Curr Opin Anaesthesiol. 2015 Aug;28(4):403-10. doi: 10.1097/ACO.0000000000000209. Review. PubMed PMID: 26087274. 6: Prabhakar A, Kaye AD, Wyche MQ, Salinas OJ, Mancuso K, Urman RD. Novel drug development for neuromuscular blockade. J Anaesthesiol Clin Pharmacol. 2016 Jul-Sep;32(3):376-8. doi: 10.4103/0970-9185.188833. PubMed PMID: 27625489; PubMed Central PMCID: PMC5009847. 7: Lien CA. Development and potential clinical impairment of ultra-short-acting neuromuscular blocking agents. Br J Anaesth. 2011 Dec;107 Suppl 1:i60-71. doi: 10.1093/bja/aer341. Review. PubMed PMID: 22156271. 8: Lien CA, Savard P, Belmont M, Sunaga H, Savarese JJ. Fumarates: unique nondepolarizing neuromuscular blocking agents that are antagonized by cysteine. J Crit Care. 2009 Mar;24(1):50-7. doi: 10.1016/j.jcrc.2008.11.001. Review. PubMed PMID: 19272539. 9: Lien CA, Belmont MR, Heerdt PM. GW280430A: pharmacodynamics and potential adverse effects. Anesthesiology. 2005 Apr;102(4):861-2; author reply 862-3. PubMed PMID: 15791118. 10: Gyermek L. Development of ultra short-acting muscle relaxant agents: history, research strategies, and challenges. Med Res Rev. 2005 Nov;25(6):610-54. Review. PubMed PMID: 16086361. 11: Savarese JJ, Belmont MR, Hashim MA, Mook RA Jr, Boros EE, Samano V, Patel SS, Feldman PL, Schultz JA, McNulty M, Spitzer T, Cohn DL, Morgan P, Wastila WB. Preclinical pharmacology of GW280430A (AV430A) in the rhesus monkey and in the cat: a comparison with mivacurium. Anesthesiology. 2004 Apr;100(4):835-45. PubMed PMID: 15087618. 12: Geldner GF, Blobner M. GW280430A. Anesthesiology. 2005 Apr;102(4):861; author reply 862-5. PubMed PMID: 15791119. 13: Heerdt PM, Kang R, The' A, Hashim M, Mook RJ Jr, Savarese JJ. Cardiopulmonary effects of the novel neuromuscular blocking drug GW280430A (AV430A) in dogs. Anesthesiology. 2004 Apr;100(4):846-51. PubMed PMID: 15087619. 14: Belmont MR, Lien CA, Tjan J, Bradley E, Stein B, Patel SS, Savarese JJ. Clinical pharmacology of GW280430A in humans. Anesthesiology. 2004 Apr;100(4):768-73. PubMed PMID: 15087609. 15: Caldwell JE. The continuing search for a succinylcholine replacement. Anesthesiology. 2004 Apr;100(4):763-4. PubMed PMID: 15087607. 16: Zhu H, Meserve K, Floyd A. Preformulation studies for an ultrashort-acting neuromuscular blocking agent GW280430A. I. Buffer and cosolvent effects on the solution stability. Drug Dev Ind Pharm. 2002;28(2):135-42. PubMed PMID: 11926357. 17: Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2005 Jan-Feb;27(1):49-77. PubMed PMID: 15834459. 18: Zhu HJ, Sacchetti M. Solid state characterization of an neuromuscular blocking agent--GW280430A. Int J Pharm. 2002 Mar 2;234(1-2):19-23. PubMed PMID: 11839434.